This site is intended for UK healthcare professionals only
This is a promotional symposium sponsored and organised by AstraZeneca.
AstraZeneca has provided a sponsorship grant towards this independent Programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations.
Professor of Cardiology, Royal Brompton Hospital
Consultant Renal Physician
Andrew has been working as a consultant nephrologist at Imperial College Healthcare NHS trust since 1995. He has extensive experience in managing all aspects of kidney disease but has a particular interest in relation to the management of diabetes in the context of kidney disease. Andrew has Maintained a significant research interest in relation to diabetes and kidney, both in terms of how diabetes affects the kidneys leading to deterioration in kidney function, but also in relation to how the presence of kidney disease influences the management of diabetes.
He is published in relation to assessment of renal complications in people with diabetes and obesity. He has also played a significant role in the development of UK national guidelines on the management of diabetes in the context of kidney disease.
Andrew is joint editor of the UK Kidney Association guidelines on the use of SGLT2I in adults with chronic kidney disease. He is also an educational leader supporting the next generation of doctors, having been the director Imperial’s Foundation School from its inception to 2010, London lead for Foundation Training 2010 to 2013 and Postgraduate Dean for South London from 2013 and 2018.
GP, Shepton Mallet and Clinical Respiratory Lead, NHS England South West and NHS Somerset
Steve has been a GP partner since 1989 and continues working clinically 5 sessions per week. He is a passionate generalist – but has a respiratory specialist interest. Steve has worked nationally and internationally on respiratory issues – and has more than 200 publications on respiratory topics. He has been involved in national and international guidelines and has worked to promote good quality care for people with long term conditions. He works on educational issues in primary and secondary care – and has involvements with the British Lung Foundation and Asthma UK as well as more local patient groups in encouraging change in practice. He has worked in service development since fundholding in the 1990s through many changes and is passionate to still make a difference. Steve enjoys music, running, watching rugby and time with his wife and two daughters.
Consultant in Diabetes, Endocrinology & Internal Medicine, Guy’s and St Thomas’ Hospital, London
Dr Karalliedde is a Clinical Reader in Diabetes and Cardiovascular Disease in the School of Cardiovascular Medicine & Sciences at King’s College London and Consultant Physician in Diabetes and Endocrinology and Internal Medicine at Guy’s and St Thomas Hospital London.
He graduated with a distinction in medicine from the University of London. He was awarded MRC Clinical Research Training Fellowship and PhD for research on the pathophysiology and treatment of cardiovascular disease and renal disease in diabetes.
Janaka has a clinical research programme focussing on new treatments to prevent diabetes related renal and cardiovascular complications. In parallel he is an active clinician with specialist clinics for patients with renal and cardiovascular complications of diabetes at Guy’s Hospital and in the community in Lambeth, south London.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its medicines are used by millions of patients worldwide.
With a proud 100-year heritage in advancing UK science, today AstraZeneca is the UK’s leading biopharmaceutical company. AstraZeneca is based in six different locations across the UK, with its global headquarters in Cambridge. In the UK, around 8,600 employees work in research and development, manufacturing, supply, sales and marketing. We supply around 35 different medicines to the NHS.
